VISCHER has advised Proteomedix AG on its licensing agreement with Immunovia AB. Proteomedix AG, a Swiss biotech subsidiary of Onconetix, Inc., has entered into a licensing...
You must be a Standard 1 Year member to access this content.
VISCHER has advised CARAUKTION. AutoScout24 has completed the acquisition of the consumer-to-business (C2B) segment previously developed in partnership with CARAUKTION, including the C2B auction platform. Effective...
You must be a Standard 1 Year member to access this content.
VISCHER has advised Medartis. Medartis, a Basel-based orthopedic company listed on the SIX Swiss Exchange, has acquired the remaining 53% stake in Geneva-based KeriMedical SA, making...
You must be a Standard 1 Year member to access this content.
VISCHER advised Forbion and Sanofi Ventures on all legal issues related to the transaction. Granite Bio AG, a clinical-stage immunology company developing first-in-class antibodies that target...
You must be a Standard 1 Year member to access this content.
VISCHER advised ImmunOs Therapeutics AG on all legal issues related to the transaction. ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on the Swiss legal aspects of the transaction. Cooley acted as lead counsel in this transaction. HAYA Therapeutics SA, a Swiss...
You must be a Standard 1 Year member to access this content.
VISCHER advised narrowin GmbH on all aspects on this transaction. The German energy supplier EnBW enters into a partnership with narrowin GmbH, a Swiss cybersecurity start-up....
You must be a Standard 1 Year member to access this content.
VISCHER advised EraCal on all legal issues related to the transaction. EraCal Therapeutics has signed a collaboration and license agreement with Danish pharma producer Novo Nordisk....
You must be a Standard 1 Year member to access this content.
VISCHER advised LASCCO SA on all legal issues related to the license agreement. LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based...
You must be a Standard 1 Year member to access this content.
VISCHER advises Epiterna with Prima Materia investment. Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro...
You must be a Standard 1 Year member to access this content.
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...
You must be a Standard 1 Year member to access this content.
Vischer advised Resistell AG on the deal. Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another...
You must be a Standard 1 Year member to access this content.
